Contact Us  |  Search  
 
The National Academies of Sciences, Engineering and Medicine
Partnerships for Enhanced Engagement in Research
Development, Security, and Cooperation
Policy and Global Affairs
Home About Us For Applicants For Grant Recipients Funded Projects Email Updates

PARTNERSHIPS FOR ENHANCED ENGAGEMENT IN RESEARCH (PEER) HEALTH
Cycle 1


Principal Investigator: Alassane Dicko, University of Bamako
NIH-Supported Collaborator: Patrick Duffy, National Institute of Allergy and Infectious Disease (NIAID)
Title of NIH Award: Malaria Immunology and Pathogenesis in Pregnant Women and Young Children

Project Overview
 
Malaria is the leading cause of morbidity and mortality in Mali. Despite effective implementation of usual control measures such as insecticide treated nets (ITN) and artemisinin combination therapy (ACT) malaria remains the number one killer in Mali. We recently showed that Seasonal Malaria Chemoprevention (SMC), previously known as Intermittent Preventive Treatment of Malaria in children, reduces malaria infection and disease by more 80% in Malian children, prompting the WHO to approve SMC as policy for countries with seasonal malaria transmission, such as Mali, in March 2012. The strategy is a highly cost-effective approach to reduce childhood mortality in these areas. Despite the huge benefit of the SMC on malaria infection and disease, the optimal approach to deliver SMC remains to be determined and there is no data on the long term effect of this strategy on the development of immunity to malaria. An optimal SMC delivery approach will make a substantial contribution toward the achievement of the goals of the US President’s Malaria Initiative (PMI) and the Millenium Development Goals. The objectives of the study are to identify the most effective method to deliver SMC, and to obtain information on the long term impact of SMC on malaria immunity. The design is a cluster-randomized trial over three years. By using a step-wedge design, the investigators aim to i) determine the optimal mode (fixed-point (FPD) vs door-to-door delivery (DDD); directly observed treatment (DOT) vs. non-DOT (NDOT)) and frequency (3 vs. 4 doses per season) of SMC delivery; ii) to compare quantitative measures of immunity in children who do and do not receive SMC over a three year period. The anticipated outcome of the study will be a qualified optimal approach to deliver SMC in Mali, and an expanded understanding of its impact on health outcomes and antimalarial immunity. The results will be shared with stakeholders, and will be used at the end of each year to guide the implementation of SMC in Mali.
 
PH 1-85 Mali photo 2PH 1-85 Mali photo 1
  

Summary of Recent Activities:

As of June 2017, the activities during this reporting period include: analysis of the molecular data, data cleaning and statistical analysis and working on manuscripts. The analysis of samples for immune responses to malaria antigens was done at MRTC in Bamako. Molecular data analysis is being performed to find if resistance markers of P. falciparum to Sulfadoxine–Pyrimethamine and Amodiaquine are present in the samples. The research project identified the optimal approach to deliver SMC in Mali to be door-to-door administration. The country has adopted this method to deliver SMC nationwide this year to improve the coverage of SMC and its impact on the malaria morbidity and mortality.

Health Cycle 1 Recipients
 
PGA_147200PGA_147199PGA_147214PGA_147201PGA_147202